US2010331277A1PendingUtilityA1

Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin

62
Individually held — no corporate assignee on recordPriority: Nov 2, 2004Filed: Mar 12, 2010Published: Dec 30, 2010
Est. expiryNov 2, 2024(expired)· nominal 20-yr term from priority
Inventors:Frank R. Prosl
A01N 43/88A61P 31/04A61K 31/185A61K 31/18A61L 29/043A61P 7/02A61L 2300/204A61K 31/727A01N 25/02A61L 29/16A61L 2300/406A61P 31/00A61L 29/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising: (A) at least one taurinamide derivative, (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof; and (C) heparin at a low concentration.

Claims

exact text as granted — not AI-modified
1 . A locking solution composition for treating and preventing infection and flow reduction in blood catheters comprising a solution of:
 a. at least one taurinamide derivative;   b. a biologically acceptable acid and a biologically acceptable salt of said acid in a combination that brings the pH of the combination into a range that enhances antimicrobial activity of the taurinamide derivative; and   c. low concentration heparin, wherein the heparin concentration is sufficient to prevent reactions of the taurinamide derivative with stagnant blood but low enough that expulsion and/or spillage of the solution into a patient's bloodstream carries a low risk of patient hemorrhage.   
     
     
         2 . The composition of  claim 1  wherein the biologically acceptable acid is chosen from the group citric acid and lactic acid and the biologically acceptable salt is chosen from the group citrate and lactate. 
     
     
         3 . The composition of  claim 1  wherein the taurinamide derivative is taurolidine, the biologically acceptable acid is citric acid, the biologically acceptable salt is citrate, and the pH range is 5.2 to 6.5. 
     
     
         4 . The composition of  claim 3  wherein low concentration heparin is in the range of 50 to 2500 units per ml. 
     
     
         5 . The composition of  claim 4  wherein low concentration heparin is in the range of 50 to 1750 units per ml. 
     
     
         6 . The composition of  claim 4  wherein low concentration heparin is in the range of 50 to 500 units per ml. 
     
     
         7 . The composition of  claim 4  wherein the low concentration heparin is in the range 50 to 150 units per ml. 
     
     
         8 . A method of enhancing the antimicrobial activity and resistance to flow reduction produced by a catheter locking solution comprising taurolidine in combination with citrate and citric acid by maintaining the pH in the range of 5.2 to 6.5 and of protecting a catheter against taurolidine reaction with blood therein by adding low concentration heparin. 
     
     
         9 . The method of  claim 8  wherein low concentration heparin is in the range of 50 to 2500 units per ml. 
     
     
         10 . The method of  claim 8  in which the low concentration heparin is in the range of 50 units per ml to 1750 units per ml. 
     
     
         11 . The method of  claim 8  in which the low concentration heparin is in the range of 50 units per ml to 500 units per ml. 
     
     
         12 . The method of  claim 8  in which the low concentration heparin is in the range of 50 units per ml to 150 units per ml. 
     
     
         13 . A composition for treating and preventing infection and patency loss in hemodialysis catheters comprising a locking solution comprising:
 a. at least one taurinamide derivative; and   b. low concentration heparin, wherein the heparin concentration is sufficient to prevent reactions of the taurinamide derivative with stagnant blood but low enough that expulsion and/or spillage of the solution into a patient's bloodstream carries a low risk of patient hemorrhage.   
     
     
         14 . The composition of  claim 13  wherein the taurinamide derivative is taurolidine. 
     
     
         15 . The composition of  claim 13  wherein heparin is added in concentration in the range of 50 to 2500 units per ml. 
     
     
         16 . The composition of  claim 13  wherein low concentration heparin is in the range of 50 to 1750 units per ml. 
     
     
         17 . The composition of  claim 13  wherein low concentration heparin is in the range of 50 to 500 units per ml. 
     
     
         18 . The composition of  claim 13  wherein the low concentration heparin is in the range 50 to 150 units per ml. 
     
     
         19 . A locking solution composition for treating and preventing infection and flow reduction in catheters comprising a solution of:
 a. at least one taurinamide derivative;   b. a biologically acceptable acid in sufficient concentration to bring the pH of the composition into a range that enhances antimicrobial activity of the taurinamide derivative; and   c. low concentration heparin, wherein the heparin concentration is sufficient to prevent reactions of the taurinamide derivative but low enough that expulsion and/or spillage of the solution into a patient's bloodstream carries a low risk of patient hemorrhage.   
     
     
         20 . The composition of  claim 19  wherein the taurinamide derivative is taurolidine. 
     
     
         21 . The composition of  claim 19  wherein heparin is added in concentration in the range of 50 to 2500 units per ml. 
     
     
         22 . The composition of  claim 19  wherein low concentration heparin is in the range of 50 to 1750 units per ml. 
     
     
         23 . The composition of  claim 19  wherein the low concentration heparin is in the range 50 to 500 units per ml. 
     
     
         24 . The composition of  claim 19  wherein the low concentration heparin is in the range 50 to 150 units per ml.

Join the waitlist — get patent alerts

Track US2010331277A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.